New hope for tough thyroid cancer? study tests cabozantinib and genetic clues

NCT ID NCT05660954

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 32 times

Summary

This study looked at how well the drug cabozantinib works for people with advanced thyroid cancer that no longer responds to radioactive iodine treatment. The main goal was to find genetic markers in the blood that might predict how the cancer responds. 41 adults took part, and researchers tracked tumor shrinkage and genetic changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, Salamanca, 37007, Spain

  • Complexo Hospitalario Universitario A Coruña

    A Coruña, A Coruña, 15006, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, 08036, Spain

  • Hospital Clínico San Carlos

    Madrid, Madrid, 28040, Spain

  • Hospital General Universitario Morales Meseguer

    Murcia, Murcia, 30008, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, 33011, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, 28034, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Barcelona, 08035, Spain

Conditions

Explore the condition pages connected to this study.